Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy

Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares; the estimated trade size was $53.42 million.

The Motley Fool • Feb 23, 2026

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead

Connecticut-based Braidwell bought 2,072,788 shares in Kodiak Sciences in the fourth quarter. The quarter-end position value increased by $57.96 million, reflecting the establishment of the new position.

The Motley Fool • Feb 19, 2026

KOD Stock Up 24% in 3 Months: Here's What You Need to Know

Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.

Zacks Investment Research • Feb 6, 2026

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.

PRNewsWire • Feb 4, 2026

These 20 stocks are strong choices for momentum investors

“Big mo” is an “eternal feature” of financial markets worldwide.

Market Watch • Jan 22, 2026

Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P.

PRNewsWire • Jan 8, 2026

What Awaits These 4 Biotech Stocks That More Than Doubled in 2025

IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.

Zacks Investment Research • Dec 22, 2025

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share.

PRNewsWire • Dec 19, 2025

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at a price to the public of $23.00 per share.

PRNewsWire • Dec 17, 2025